 |
 |
A Therapeutic Step towards Health
Rhemacell 2G
Material and Methods:
30 patients with a clinical diagnosis of rheumatoid arthritis were studied. At the start of the study, a sample was taken from all of them of synovial fluid extracted from their knees. This was done using an articular puncture fine point needle, after administering anaesthesia with lidocaine 1% in the periarticular area, extracting a total sample of 1 cc, which was processed by means of immunoelectrophoresis to determine the presence of mucopolysaccharides, as well as a cellular study to determine the presence of PMN. Subsequently, they underwent a protocol of administration of Rhemacell 2G (2 cc) for a period of six months, during which they were injected IM every other day for three months, continuing with the administration of 1500 mg (6 coated tablets) daily for three months. At the end of this period, a new synovial fluid sample is taken and the clinical parameters are evaluated.
Results:
The following results were obtained: Out of the 30 patients, 24 (80%) experienced a clinical improvement of their symptoms, both as regards morning stiffness and arthritis in their hand joints. PMN counts decreased in 27 patients (90%), of the sampling.
05 10 15 20 25 30 Improvement No Improvement Patient
 |
||
More Information |
||
| » Rhemacell 2G » Clinical Information and Pharmacology » Mechanisms of Action » Pharmacokinetics |
» Indications » Contraindications » Toxicity » Clinical Studies |
» Conclusions
» Material and Methods » References |